Refine by
Covid 19 Novel Vaccination Articles & Analysis
106 news found
In an epidemic, better knowledge can lead to wiser policy and can save lives. Can wastewater-based measurements of SARS-CoV-2 activity help us understand the effects of COVID-19 vaccination, and how those effects might change with new variants like Delta? To understand how wastewater can help us better understand the role of vaccines during this Delta wave, we should first look back to how we ...
Jamie Triccas) which, together with ExcellGene, constitutes a three – party consortium funded by CEPI with a grant of 19 million US dollars. The project has the goal to develop a “Pan-protective SARS-CoV-2 vaccine” hoping to show protection against all past and future variant of concern of the Corona virus. ...
BOC Sciences expressed its congratulations to Katalin Karikó and Drew Weissman for being recipients of the 2023 Nobel Prize in Physiology or Medicine. The Royal Swedish Academy of Sciences recognized Dr. Karikó and Dr. Weissman's remarkable contributions to science, specifically acknowledging their game-changing discoveries in nucleoside base modifications. BOC Sciences, which ...
Emalfarb concluded. “The COVID-19 pandemic brought mRNA technology to the forefront, showing its potential to prevent and treat diseases. ...
"End-to-End Support for Your Pharmaceutical Journey", with the commitment to researchers, BOC Sciences will attend the renowned World Vaccine Congress Europe in Barcelona, Spain, from 16 to 19 Octobe World Vaccine Congress Europe has become the world's largest and most established meeting dedicated to vaccines. It brings together the professionals and companies that are shaping the future of ...
HM King Philippe and HM Queen Mathilde, currently on a state visit to South Africa until March 27, visited the Afrigen Biologics facility in Cape Town to learn more about how two Belgian companies, Univercells and etherna, are supporting the development of the first African- developed mRNA COVID-19 vaccine. The King and The Queen are accompanied by five ministers of federal and regional ...
ByeTheRNA
VeriSIM Life has been awarded a National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $255,908 to conduct research and development (R&D) work on rapid repurposing and translation of approved and investigational drugs for COVID-19 using its patented artificial intelligence (AI) driven biosimulation platform, BIOiSIM. VeriSIM Life has developed a whole-body ...
Follows recent financing round led by Novalis LifeSciences LLC, with investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien joining the board of directors Strategic focus includes customized lipid nanoparticles (cLNPs) mRNA chemistries and process capabilities as enabling technologies driving company excellence etherna (“the Company”), a leading ...
ByeTheRNA
IRVINE, Calif. – OCT. 4, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced that the Journal of Oncology Research and Therapy has published data from its completed Phase 2 glioblastoma (GBM) study which demonstrates enhanced progression-free survival (PFS). The publication, titled “Enhanced Progression-Free Survival in ...
In recognition of his commitment to innovation and entrepreneurial spirit, Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, has been named as one of seven Pacific winners in the EY Entrepreneur of the Year Award Program. He and the other Pacific award winners will go on to compete for 10 national titles and the overall top spot in Canada at the EY virtual celebration in November ...
With an expanded portfolio and increasing technical, regulatory, and market challenges for COVID-19 vaccine development, we have decided not to proceed with an IND submission for IBIO-202, our multi-variant COVID-19 vaccine candidate. ...
Biolingus IP II GmbH and the CHA Vaccine Institute Co., Ltd., with support from the Korean biotech company PanGen Biotech Inc., will collaborate to develop a sublingual vaccine for COVID. The project has received research funding from The Research Investment for Global Health Technology Fund (The RIGHT Fund). The RIGHT Fund is a Public-Private Partnership (PPP) funding agency between the ...
The deadliest of these parasites is Plasmodium falciparum, and Ocean Biomedical’s vaccine and therapeutic candidates target PfGARP and PfSEA-1 –novel targets discovered by Scientific Co-Founder Dr. ...
IRVINE, Calif. – AUG. 29, 2022 – AIVITA Biomedical, Inc., a biotech company specializing in innovative cell applications, today announced the publication of safety and efficacy results from Phase 1 and Phase 2 clinical trials investigating its anti-SARS-CoV-2 vaccine candidate AV-COVID-19 that is made at point-of-care by third-party personnel. The results were published in the article ...
Michael Artley has joined Acuitas Therapeutics as Senior Director of Information Technology (IT), Abi Coman-Walker, Acuitas’ Chief Operating Officer, announced recently. Mr. Artley will lead the company’s commitment in ensuring that information, systems, data and innovation continue to support Acuitas Therapeutics in its global mission of advancing human health. Prior to joining the ...
Dr. Mark Prausnitz, co-founder and Chief Scientific Advisor of Micron Biomedical (“Micron”), today presented Micron’s technology for the simple administration of vaccines and therapeutics at a White House panel discussion titled Innovation in Vaccine Delivery chaired by Dr. Francis Collins. This summit outlined a path toward innovative, next-generation COVID-19 vaccines and ...
Clínica Universidad de Navarra has completed a randomised controlled study of Ondine Biomedical’s nasal photodisinfection technology in fully vaccinated COVID-19 patients with early symptoms of COVID-19. “Top-line results from this clinical trial suggest that nasal photodisinfection treatment rapidly and substantially suppresses SARS-CoV-2 viral replication and infectivity in ...
Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, is pleased to announce that Acuitas has been recognized as Company of the Year by Life Sciences BC (LSBC). Acuitas Therapeutics’ co-founder, Dr. Pieter Cullis, is this year’s recipient of LSBC’s Global Impact Award. “We are honoured to have Acuitas Therapeutics named as Company of the Year by Life Sciences ...
Ziphius Vaccines is developing a proprietary self-amplifying mRNA technology platform combined with innovative lipid formulations for delivery. saRNA or replicon RNA has the advantage of having self-replicating features, as the saRNA molecule encodes a viral RNA replicase in addition to the sequence of the protein(s) of interest. This mechanism leads to enhanced and prolonged protein ...
Koen Augustyns, dean of the Faculty of Pharmaceutical, Biomedical and Veterinary Sciences University of Antwerp, commenting on today’s announcement, stated: “Everyone got to know about mRNA vaccines during the Covid-19 crisis. In future, we expect a lot from saRNA vaccines, their successors. ...